The Prothrombotic State in Rheumatoid Arthritis: An Additive Risk Factor for Adverse Cardiovascular Events

 

 Buy Article Permissions and Reprints

ABSTRACT

Rheumatoid arthritis (RA) has been recognized to increase cardiovascular morbidity and mortality independent of established risk factors. The chronic inflammatory state, a hallmark of RA, is considered an autonomous risk factor, whereas components of innate and adaptive immunity are believed to contribute to the onset of acute cardiovascular events. Several studies have suggested that RA confers a prothrombotic state featured by abnormalities in coagulation and fibrinolytic systems together with an altered state of platelet reactivity. It is conceivable that these findings may be partly instrumental for the observed increased risk for adverse cardiovascular events in RA. Therapeutic strategies aimed at attenuating the inflammatory disease activity and intervening at the point of cross-talk between mediators of inflammation and thrombogenesis may help reduce cardiovascular disease burden in patients with RA.

REFERENCES

• 1 Solomon D H, Karlson E W, Rimm E B et al.. Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis.  Circulation. 2003;  107(9) 1303-1307
  CrossrefPubMedGoogle Scholar
• 2 Wolfe F, Mitchell D M, Sibley J T et al.. The mortality of rheumatoid arthritis.  Arthritis Rheum. 1994;  37(4) 481-494
  CrossrefPubMedGoogle Scholar
• 3 Naranjo A, Sokka T, Descalzo M A QUEST-RA Group et al. Cardiovascular disease in patients with rheumatoid arthritis: results from the QUEST-RA study.  Arthritis Res Ther. 2008;  10(2) R30
  CrossrefPubMedGoogle Scholar
• 4 Bisoendial R J, Stroes E S, Tak P P. Where the immune response meets the vessel wall.  Neth J Med. 2009;  67(8) 328-333
  PubMedGoogle Scholar
• 5 Libby P. Inflammation in atherosclerosis.  Nature. 2002;  420(6917) 868-874
  CrossrefPubMedGoogle Scholar
• 6 Blanco-Colio L M, Muñoz-García B, Martín-Ventura J L et al.. 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors decrease Fas ligand expression and cytotoxicity in activated human T lymphocytes.  Circulation. 2003;  108(12) 1506-1513
  CrossrefPubMedGoogle Scholar
• 7 Loscalzo J. Nitric oxide insufficiency, platelet activation, and arterial thrombosis.  Circ Res. 2001;  88(8) 756-762
  CrossrefPubMedGoogle Scholar
• 8 Björkerud S, Björkerud B. Apoptosis is abundant in human atherosclerotic lesions, especially in inflammatory cells (macrophages and T cells), and may contribute to the accumulation of gruel and plaque instability.  Am J Pathol. 1996;  149(2) 367-380
  PubMedGoogle Scholar
• 9 Flynn P D, Byrne C D, Baglin T P, Weissberg P L, Bennett M R. Thrombin generation by apoptotic vascular smooth muscle cells.  Blood. 1997;  89(12) 4378-4384
  PubMedGoogle Scholar
• 10 Butenas S, Orfeo T, Mann K G. Tissue factor in coagulation: Which? Where? When?.  Arterioscler Thromb Vasc Biol. 2009;  29(12) 1989-1996
  CrossrefPubMedGoogle Scholar
• 11 Creager M A, Lüscher T F, Cosentino F, Beckman J A. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part I.  Circulation. 2003;  108(12) 1527-1532
  CrossrefPubMedGoogle Scholar
• 12 MacCallum P K, Rudnicka A R, Rumley A, Meade T W, Lowe G D. Low-intensity warfarin reduces thrombin generation and fibrin turnover, but not low-grade inflammation, in men at risk of myocardial infarction.  Br J Haematol. 2004;  127(4) 448-450
  CrossrefPubMedGoogle Scholar
• 13 McEntegart A, Capell H A, Creran D, Rumley A, Woodward M, Lowe G D. Cardiovascular risk factors, including thrombotic variables, in a population with rheumatoid arthritis.  Rheumatology (Oxford). 2001;  40(6) 640-644
  CrossrefPubMedGoogle Scholar
• 14 Wållberg-Jonsson S, Cvetkovic J T, Sundqvist K G, Lefvert A K, Rantapää-Dahlqvist S. Activation of the immune system and inflammatory activity in relation to markers of atherothrombotic disease and atherosclerosis in rheumatoid arthritis.  J Rheumatol. 2002;  29(5) 875-882
  PubMedGoogle Scholar
• 15 Ingegnoli F, Fantini F, Favalli E G et al.. Inflammatory and prothrombotic biomarkers in patients with rheumatoid arthritis: effects of tumor necrosis factor-alpha blockade.  J Autoimmun. 2008;  31(2) 175-179
  CrossrefPubMedGoogle Scholar
• 16 Angiolillo D J, Bernardo E, Sabaté M et al.. Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease.  J Am Coll Cardiol. 2007;  50(16) 1541-1547
  CrossrefPubMedGoogle Scholar
• 17 Harrison P, Keeling D. Platelet hyperactivity and risk of recurrent thrombosis.  J Thromb Haemost. 2006;  4(12) 2544-2546
  CrossrefPubMedGoogle Scholar
• 18 Riddle J M, Bluhm G B, Pitchford W C et al.. A comparative study of platelet reactivity in arthritis.  Ann N Y Acad Sci. 1981;  370 22-29
  CrossrefPubMedGoogle Scholar
• 19 Wang F, Wang N S, Yan C G, Li J H, Tang L Q. The significance of platelet activation in rheumatoid arthritis.  Clin Rheumatol. 2007;  26(5) 768-771
  CrossrefPubMedGoogle Scholar
• 20 Mac Mullan P A, Peace A J, Madigan A M, Tedesco A F, Kenny D, McCarthy G M. Platelet hyper-reactivity in active inflammatory arthritis is unique to the adenosine diphosphate pathway: a novel finding and potential therapeutic target.  Rheumatology (Oxford). 2010;  49(2) 240-245
  CrossrefPubMedGoogle Scholar
• 21 Levi M, van der Poll T. The role of natural anticoagulants in the pathogenesis and management of systemic activation of coagulation and inflammation in critically ill patients.  Semin Thromb Hemost. 2008;  34(5) 459-468
  Article in Thieme ConnectPubMedGoogle Scholar
• 22 Kobayashi S, Inoue N, Ohashi Y et al.. Interaction of oxidative stress and inflammatory response in coronary plaque instability: important role of C-reactive protein.  Arterioscler Thromb Vasc Biol. 2003;  23(8) 1398-1404
  CrossrefPubMedGoogle Scholar
• 23 Sattler K J, Woodrum J E, Galili O et al.. Concurrent treatment with renin-angiotensin system blockers and acetylsalicylic acid reduces nuclear factor kappaB activation and C-reactive protein expression in human carotid artery plaques.  Stroke. 2005;  36(1) 14-20
  CrossrefPubMedGoogle Scholar
• 24 Torzewski J, Torzewski M, Bowyer D E et al.. C-reactive protein frequently colocalizes with the terminal complement complex in the intima of early atherosclerotic lesions of human coronary arteries.  Arterioscler Thromb Vasc Biol. 1998;  18(9) 1386-1392
  CrossrefPubMedGoogle Scholar
• 25 Yasojima K, Schwab C, McGeer E G, McGeer P L. Generation of C-reactive protein and complement components in atherosclerotic plaques.  Am J Pathol. 2001;  158(3) 1039-1051
  CrossrefPubMedGoogle Scholar
• 26 Turk J R, Carroll J A, Laughlin M H et al.. C-reactive protein correlates with macrophage accumulation in coronary arteries of hypercholesterolemic pigs.  J Appl Physiol. 2003;  95(3) 1301-1304
  PubMedGoogle Scholar
• 27 Sun H, Koike T, Ichikawa T et al.. C-reactive protein in atherosclerotic lesions: its origin and pathophysiological significance.  Am J Pathol. 2005;  167(4) 1139-1148
  CrossrefPubMedGoogle Scholar
• 28 Inoue T, Kato T, Uchida T et al.. Local release of C-reactive protein from vulnerable plaque or coronary arterial wall injured by stenting.  J Am Coll Cardiol. 2005;  46(2) 239-245
  CrossrefPubMedGoogle Scholar
• 29 Verma S, Wang C H, Li S H et al.. A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis.  Circulation. 2002;  106(8) 913-919
  CrossrefPubMedGoogle Scholar
• 30 Venugopal S K, Devaraj S, Yuhanna I, Shaul P, Jialal I. Demonstration that C-reactive protein decreases eNOS expression and bioactivity in human aortic endothelial cells.  Circulation. 2002;  106(12) 1439-1441
  CrossrefPubMedGoogle Scholar
• 31 Mineo C, Gormley A K, Yuhanna I S et al.. FcgammaRIIB mediates C-reactive protein inhibition of endothelial NO synthase.  Circ Res. 2005;  97(11) 1124-1131
  CrossrefPubMedGoogle Scholar
• 32 Qamirani E, Ren Y, Kuo L, Hein T W. C-reactive protein inhibits endothelium-dependent NO-mediated dilation in coronary arterioles by activating p38 kinase and NAD(P)H oxidase.  Arterioscler Thromb Vasc Biol. 2005;  25(5) 995-1001
  CrossrefPubMedGoogle Scholar
• 33 Venugopal S K, Devaraj S, Jialal I. C-reactive protein decreases prostacyclin release from human aortic endothelial cells.  Circulation. 2003;  108(14) 1676-1678
  CrossrefPubMedGoogle Scholar
• 34 Cermak J, Key N S, Bach R R, Balla J, Jacob H S, Vercellotti G M. C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor.  Blood. 1993;  82(2) 513-520
  PubMedGoogle Scholar
• 35 Paffen E, Vos H L, Bertina R M. C-reactive protein does not directly induce tissue factor in human monocytes.  Arterioscler Thromb Vasc Biol. 2004;  24(5) 975-981
  CrossrefPubMedGoogle Scholar
• 36 Cirillo P, Golino P, Calabrò P et al.. C-reactive protein induces tissue factor expression and promotes smooth muscle and endothelial cell proliferation.  Cardiovasc Res. 2005;  68(1) 47-55
  CrossrefPubMedGoogle Scholar
• 37 Devaraj S, Xu D Y, Jialal I. C-reactive protein increases plasminogen activator inhibitor-1 expression and activity in human aortic endothelial cells: implications for the metabolic syndrome and atherothrombosis.  Circulation. 2003;  107(3) 398-404
  CrossrefPubMedGoogle Scholar
• 38 Singh U, Devaraj S, Jialal I. C-reactive protein decreases tissue plasminogen activator activity in human aortic endothelial cells. Evidence that C-reactive protein is a procoagulant.  Arterioscler Thromb Vasc Biol. 2005;  25(10) 2216-2221
  CrossrefPubMedGoogle Scholar
• 39 Grad E, Golomb M, Koroukhov N et al.. Aspirin reduces the prothrombotic activity of C-reactive protein.  J Thromb Haemost. 2009;  7(8) 1393-1400
  CrossrefPubMedGoogle Scholar
• 40 Bisoendial R J, Kastelein J J, Peters S L et al.. Effects of CRP infusion on endothelial function and coagulation in normocholesterolemic and hypercholesterolemic subjects.  J Lipid Res. 2007;  48(4) 952-960
  CrossrefPubMedGoogle Scholar
• 41 Meek R L, Urieli-Shoval S, Benditt E P. Expression of apolipoprotein serum amyloid A mRNA in human atherosclerotic lesions and cultured vascular cells: implications for serum amyloid A function.  Proc Natl Acad Sci U S A. 1994;  91(8) 3186-3190
  CrossrefPubMedGoogle Scholar
• 42 Zhao Y, Zhou S, Heng C K. Impact of serum amyloid A on tissue factor and tissue factor pathway inhibitor expression and activity in endothelial cells.  Arterioscler Thromb Vasc Biol. 2007;  27(7) 1645-1650
  CrossrefPubMedGoogle Scholar
• 43 Cai H, Song C, Endoh I et al.. Serum amyloid A induces monocyte tissue factor.  J Immunol. 2007;  178(3) 1852-1860
  PubMedGoogle Scholar
• 44 He R, Sang H, Ye R D. Serum amyloid A induces IL-8 secretion through a G protein-coupled receptor, FPRL1/LXA4R.  Blood. 2003;  101(4) 1572-1581
  CrossrefPubMedGoogle Scholar
• 45 Bauer K A, ten Cate H, Barzegar S, Spriggs D R, Sherman M L, Rosenberg R D. Tumor necrosis factor infusions have a procoagulant effect on the hemostatic mechanism of humans.  Blood. 1989;  74(1) 165-172
  PubMedGoogle Scholar
• 46 van der Poll T, Büller H R, ten Cate H et al.. Activation of coagulation after administration of tumor necrosis factor to normal subjects.  N Engl J Med. 1990;  322(23) 1622-1627
  CrossrefPubMedGoogle Scholar
• 47 Anderson H D, Rahmutula D, Gardner D G. Tumor necrosis factor-alpha inhibits endothelial nitric-oxide synthase gene promoter activity in bovine aortic endothelial cells.  J Biol Chem. 2004;  279(2) 963-969
  CrossrefPubMedGoogle Scholar
• 48 Nawroth P P, Bank I, Handley D, Cassimeris J, Chess L, Stern D. Tumor necrosis factor/cachectin interacts with endothelial cell receptors to induce release of interleukin 1.  J Exp Med. 1986;  163(6) 1363-1375
  CrossrefPubMedGoogle Scholar
• 49 Faust S N, Levin M, Harrison O B et al.. Dysfunction of endothelial protein C activation in severe meningococcal sepsis.  N Engl J Med. 2001;  345(6) 408-416
  CrossrefPubMedGoogle Scholar
• 50 Jansen P M, Boermeester M A, Fischer E et al.. Contribution of interleukin-1 to activation of coagulation and fibrinolysis, neutrophil degranulation, and the release of secretory-type phospholipase A2 in sepsis: studies in nonhuman primates after interleukin-1 alpha administration and during lethal bacteremia.  Blood. 1995;  86(3) 1027-1034
  PubMedGoogle Scholar
• 51 Stouthard J M, Levi M, Hack C E et al.. Interleukin-6 stimulates coagulation, not fibrinolysis, in humans.  Thromb Haemost. 1996;  76(5) 738-742
  PubMedGoogle Scholar
• 52 Lauw F N, Dekkers P E, te Velde A A et al.. Interleukin-12 induces sustained activation of multiple host inflammatory mediator systems in chimpanzees.  J Infect Dis. 1999;  179(3) 646-652
  CrossrefPubMedGoogle Scholar
• 53 Portielje J E, Kruit W H, Eerenberg A J et al.. Interleukin 12 induces activation of fibrinolysis and coagulation in humans.  Br J Haematol. 2001;  112(2) 499-505
  CrossrefPubMedGoogle Scholar
• 54 Hermann A, Rauch B H, Braun M, Schrör K, Weber A A. Platelet CD40 ligand (CD40L)—subcellular localization, regulation of expression, and inhibition by clopidogrel.  Platelets. 2001;  12(2) 74-82
  CrossrefPubMedGoogle Scholar
• 55 Pignatelli P, Cangemi R, Celestini A et al.. Tumour necrosis factor alpha upregulates platelet CD40L in patients with heart failure.  Cardiovasc Res. 2008;  78(3) 515-522
  CrossrefPubMedGoogle Scholar
• 56 So A K, Varisco P A, Kemkes-Matthes B et al.. Arthritis is linked to local and systemic activation of coagulation and fibrinolysis pathways.  J Thromb Haemost. 2003;  1(12) 2510-2515
  CrossrefPubMedGoogle Scholar
• 57 Busso N, Morard C, Salvi R, Péclat V, So A. Role of the tissue factor pathway in synovial inflammation.  Arthritis Rheum. 2003;  48(3) 651-659
  CrossrefPubMedGoogle Scholar
• 58 Busso N, Hamilton J A. Extravascular coagulation and the plasminogen activator/plasmin system in rheumatoid arthritis.  Arthritis Rheum. 2002;  46(9) 2268-2279
  CrossrefPubMedGoogle Scholar

Radjesh BisoendialM.D. Ph.D. 

Department Internal Medicine (F-4), Academic Medical Center

University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands

Email: r.j.bisoendial@amc.uva.nl